Eric Q. Parkhill

Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors

Dmitry O. Koltun, Eric Q. Parkhill, Natalya I. Vasilevich et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 55 citations · Full text

Biochemistry, Stable Stearoyl-coa Desaturase, Medicine +9

Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors

Dmitry O. Koltun, Natalya I. Vasilevich, Eric Q. Parkhill et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 44 citations · Full text

Pharmaceutical Science, Medicine, Drug Discovery +4

Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists

Elfatih Elzein, Rao Kalla, Xiaofen Li et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 44 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry +9

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine

Dmitry O. Koltun, Eric Q. Parkhill, Elfatih Elzein et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 40 citations

Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late <i>I</i>_Nai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties

Jeff Zablocki, Elfatih Elzein, Xiaofen Li et al. · Journal of Medicinal Chemistry · 2016 · 34 citations · Full text